Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial
- 20 April 2022
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (12), 1335-1345
- https://doi.org/10.1200/jco.21.02019
Abstract
Patients with 70-gene signature ultralow-risk breast cancers have shown excellent survival in historic cohorts, including randomized trials. The ultralow-risk subgroup was characterized to help avoid overtreatment. We evaluated outcomes of ultralow-risk patients in the largest cohort to date. Of the 6,693 patients enrolled in the EORTC-10041/BIG-3-04 randomized phase III MINDACT trial, profiling revealed an ultralow-risk 70-gene signature in 1,000 patients (15%). Distant metastasis-free interval (DMFI) and breast cancer–specific survival (BCSS) were assessed in patients stratified by 70-gene signature result (high, low, and ultralow) by Kaplan-Meier analysis and hazard ratios with 95% CI from Cox regression. Median follow-up was 8.7 years. Of the ultralow-risk patients (n = 1,000), 67% were > 50 years, 81% had tumors ≤ 2 cm, 80% were lymph node–negative, 96% had grade 1 or 2 tumors, and 99% were estrogen receptor (ER)-positive. Systemic therapy was received by 84% of patients (69% endocrine therapy, 14% endocrine therapy plus chemotherapy, 1% other) and 16% received no adjuvant systemic treatment. The 8-year DMFI for ultralow-risk patients was 97.0% (95% CI, 95.8 to 98.1), which was 2.5% higher than for patients with low-risk tumors (n = 3,295, 94.5% [95% CI, 93.6 to 95.3]). The hazard ratio for DMFI was 0.65 (95% CI, 0.45 to 0.94) for ultralow versus low risk, after adjusting for clinical-pathologic and treatment characteristics. The 8-year BCSS for ultralow-risk patients was 99.6% (95% CI, 99.1 to 100). Patients with an ultralow-risk 70-gene signature have the best prognosis, distinctive from low risk, with 8-year BCSS above 99%, and very few patients developed distant metastases with an 8-year DMFI rate of 97%. These patients could be candidates for further de-escalation of treatment, to avoid overtreatment and the risk of side effects.Keywords
This publication has 35 references indexed in Scilit:
- Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention SettingsCancer Prevention Research, 2014
- Mammographic screening detects low-risk tumor biology breast cancersBreast Cancer Research and Treatment, 2014
- The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancerJournal of Clinical Pathology, 2014
- Impact of mammographic screening on the detection of good and poor prognosis breast cancersBreast Cancer Research and Treatment, 2011
- Prognosis and pathology of screen‐detected carcinomasCancer, 2010
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology, 2010
- Rethinking Screening for Breast Cancer and Prostate CancerJAMA, 2009
- Reducing the Risk of Distant Metastases: A Better End Point in Adjuvant Aromatase Inhibitor Breast Cancer Trials?Cancer Investigation, 2008
- Competing risk analysis using R: an easy guide for cliniciansBone Marrow Transplantation, 2007
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002